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Summary The goal of this study was to investigate the efficacy of photodynamic therapy (PDT) of a single
tumour growing intraperitoneally. For this purpose the CC531 colon carcinoma, implanted in an
intraperitoneal fat pad of Wag/RijA rats, was treated with intraperitoneal photodynamic therapy (IPPDT)
using Photofrin as the photosensitiser. Two illumination techniques have been compared. An invasive
illumination technique using Perspex blocks to illuminate 30 cm2 of the lower abdomen gave a significant delay
in tumour growth with 25 J cm-2 applied 1 day after Photofrin. A minimally invasive illumination technique
using a balloon catheter to illuminate 14 cm2 resulted in an equivalent growth delay with 75 J cm-2. The route
of administration of the photosensitiser did not influence regrowth times of the tumour. Mitomycin C (MMC),
a bioreductive agent, was used to exploit the known PDT-induced hypoxia. The combination of IPPDT with
MMC resulted in an increased tumoricidal effect. In conclusion, IPPDT led to a significant growth delay for a
single tumour implanted intraperitoneally and repetition of the PDT treatment was possible using a minimally
invasive illumination technique. Repeated treatments resulted in increased tumour response.
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The treatment of minimal residual peritoneal cancer is an
ongoing oncological challenge because of the poor survival
figures. About 35% of patients with microscopic residual
disease from ovarian cancer survive 5 years (Neijt et al.,
1991). For patients with peritoneal metastases from colorectal
cancer the median survival is between 3 and 12 months
(Turnbull et al., 1989). The multiple, small superficial
tumours are usually confined to the peritoneum and should
be suitable for local treatment. Photodynamic therapy (PDT)
could be especially applicable for these peritoneally growing
tumours, if illumination of the peritoneum can be achieved.
PDT involves the systemic administration of a photosensitiser
combined with local excitation of the photosensitiser, after a
distribution interval. The photosensitiser is excited with light
of a wavelength corresponding to an absorption peak of the
sensitiser. The excited photosensitiser generates highly
reactive toxic species (singlet oxygen and free radicals). The
limited penetration depth of light used to excite Photofrin,
the photosensitiser used in this study, restricts normal tissue
toxicity to a maximum depth of about 1 cm. In small animal
studies even this limited penetration depth can lead to
substantial toxicity but the more bulky human organs will be
relatively spared by their volume (DeLaney et al., 1993;
Veenhuizen et al., 1994).
Several preclinical studies have investigated the toxicity
and efficacy of IPPDT in a variety of species. Haematopor-
phyrin derivative (HPD)-mediated IPPDT in rats appeared to
disrupt intestinal blood flow (Selman et al., 1985), although
other studies demonstrated no serious damage to major
blood vessels in rats treated with HPD mediated IPPDT
(Suzuki et al., 1987). In dogs, only mild inflammatory
responses were found after treatment of the entire peritoneal
cavity with 0.57-0.74 J cm-2 48 h after Photofrin
(1.25 mg kg-')(Tochner et al., 1991). In rabbits and baboons
treated with HPD-mediated IPPDT, the liver and intestines
appeared to be most sensitive to damage (Douglass et al.,
1981).
The first tumour results on IPPDT date from 1981
(Douglass et al., 1981), where apparent necrosis of Brown-
Pierce tumours in rabbits (implanted in serosa of the bowel,
liver, pancreas or bladder) was reported 5-7 days after
treatment with HPD (5 mg kg-') and light. Red laser light
(631 nm) was delivered through 200 gm diameter quartz glass
fibres to illuminate a 1 cm diameter spot on the surface ofthe
tumour. In this study extremely high fluences (300 J cm-2)
and fluence rates (260-1400 mW cm-2) were used. Some
hyperthermia was almost certainly associated with these
treatments, which therefore cannot directly be compared
with other studies. More clinically relevant studies are
reported by Tochner et al. (1985, 1986) in which a murine
ascites model was treated with HPD (50 mg kg-1) and 9.6 J
of green (less penetrating) laser light of 514 nm wavelength.
This treatment resulted in 6% cures after one PDT session
and 37% and 85% cures after two and four PDT treatments
respectively. In this study HPD was injected 2 h before each
illumination. These results, together with the toxicity results
in dogs, formed the basis for the only published phase I
clinical trial for IPPDT to date (Sindelar et al., 1991;
DeLaney et al., 1993). This trial demonstrated the feasibility
of delivering PDT to the peritoneal cavity at the time of
laparotomy. Considering the limited available literature, we
concluded that minimal residual peritoneal cancer presents an
attractive challenge for IPPDT and that this is worthy of
further investigation.
In this study several IPPDT regimens were investigated in
a rat tumour model. An intraperitoneal (i.p.) implantable
colon carcinoma was used, since there is no rat ovarian
carcinoma available. Intraperitoneal administration of the
photosensitiser was studied with the aim of directly exposing
the i.p. tumour to a high concentration of the photosensitiser.
In addition, mitomycin C (MMC) was combined with PDT
in an attempt to exploit the tumour hypoxia known to occur
after PDT (Star et al., 1986; van Geel et al., 1994). MMC is a
cytostatic antibiotic that exerts its cytotoxicity by selectively
inhibiting DNA synthesis (Verweij and Pinedo, 1990;
Sartorelli, 1988). Under hypoxic conditions the efficacy of
MMC is 2-3 times greater than in oxic conditions
(Rockwell, 1986). Finally, the feasibility and efficacy of
repeated IPPDT treatments were investigated using a minimal
access illumination technique. The efficacy of IPPDT is
compared with the best tested chemotherapy in this
preclinical model: cisplatin.
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Materials and methods
Animal model
Female Wag/RijA rats weighing 150-200 g (aged 10-12
weeks) were obtained from the animal department of the
Netherlands Cancer Institute. The animals were bred under
specific pathogen-free (SPF) conditions and housed in
polycarbonate cages (Makrolon III, 1-3 rats per cage) on
presterilised wood shavings in animal rooms under controlled
conditions (artificial lighting from 07.00 to 19.00 h; 15 air
changes per hour, 220C and relative humidity of 55%). After
administration of photosensitiser the rats were kept in
subdued light for 2 weeks. They were fed standard rat chow
(Hope Farms AM II) and acidified water ad libitum. All
experiments were carried out in accordance with protocols
approved by the experimental animal welfare committee of
the institute and conformed to national and European
regulations for animal experimentation.
Tumour model
The CC531 colon carcinoma cell line was used in all
experiments. This is a moderately differentiated adenocarci-
noma of the rat colon (Nagel et al., 1990). The CC531 cells
were grown in culture flasks in Dulbecco's modified Eagle
medium (DMEM) with 10% fetal calf serum (FCS), penicillin
and streptomycin. A single cell suspension was prepared by
trypsinisation, counting in a haemocytometer, centrifuging
(1000 r.p.m., 5 min) and suspending in phosphate-buffered
saline (5 x 106 cells ml-'). This suspension (0.2 ml) was
inoculated on the thigh of a donor rat. After 4-5 weeks a
solid tumour with a diameter of 1-2 cm was developed. The
tumour was excised and cut into slices of + 1.5 mm thickness.
Cylinders of 3 mm diameter were punched from slices of the
viable outer rim of the tumour. These cylinders were halved
and kept in saline. Immediately after preparation the pieces
were implanted in a fat pad in the lower abdomen of female
Wag/RijA rats. The rats were anaesthetised with ether and
the abdominal skin was shaved and cleaned with 70%
ethanol. A median incision of 0.5-1.0 cm was made in the
abdominal wall. A fat pad from the lower abdomen was
gently pulled out and exposed on the abdominal wall, a
tumour piece was placed on the fat pad and the fat was
folded over the tumour and sutured with silk (5-0). The fat
pad was replaced in the lower abdomen and the abdominal
cavity was closed in one layer with 3-0 silk sutures. After 7
days the tumour had grown to a diameter of about 5 mm and
was used for treatment.
Photosensitizers
Photofrin (batch number: B91-0124, Lederle Etten-Leur, The
Netherlands) was provided as a freeze-dried preparation,
which was dissolved in 5% glucose to a concentration of
2 mg ml-'. The stock solution was then divided into aliquots
and stored in the dark at -20°C until required (stock
solutions were thawed and brought to room temperature
once only before injection). Photofrin was given 24 h before
illumination, at a dose of 5 mg kg-1, injected intravenously
(i.v.) via tail vein. For i.p. injection the proper amount of
photosensitiser per rat was dissolved in 3.5 ml of lukewarm
saline 3 h or 24 h before illumination.
Chemotherapeutic drugs
The hypoxic toxin Mitomycin C (MMC, Kyowa, Christiaens
Etten Leur, The Netherlands) was administered i.v. via the tail
vein at a drug dose of 1.5 mg kg-'. MMC alone caused little
acute toxicity (i.e. 3% weight loss in the first week). Post-
injection flushing with saline ensured that MMC was not
injected or spilled subcutaneously. Subcutaneous injection of
MMC caused severe necrosis of the injection site leading to
intolerable morbidity. Cisplatin (Platinol, Bristol-Myers
Squibb Woerden, The Netherlands) was supplied as a solution
of 0.5 mg ml-1 in 20 ml of sodium chloride 0.9% and
hydrochloric acid in water at pH 2-3. Drug doses of 2 and
4 mg kg-1 (maximum tolerable) were used. Beforei.p. injection
cisplatin was dissolved in 13 -14 ml of lukewarm saline.
Illumination procedure
For the initial series of experiments an invasive illumination
procedure with Perspex light delivery blocks inserted into the
lower abdomen was used (illumination protocol 1). This
technique had the advantage that the light distribution over
the entire lower abdomen could be accurately described for
all tissues in direct contact with the blocks. The disadvantage
of illumination protocol 1 was that it required large (5 cm)
surgical incisions into the abdomen and was too invasive to
be repeated. A second illumination procedure (protocol 2)
was therefore also developed and tested, employing an
inflatable balloon as the light source. This procedure had
the advantage of being minimally invasive, thus permitting
repeated treatments, but had the disadvantage of a less
uniform light distribution over the lower abdomen. These
two illumination procedures are described below.
Illumination protocol I Rats were anaesthetised with an
intramuscular injection of 0.1 ml Aescoket plus (ketamine,
xylazine and atropine) for illumination of the lower abdo-
men. They were kept warm (rectal temperature 35-38°C) on
an electrical heating pad. A median incision of approximately
5 cm was made in the abdominal wall. The intestines were
gently exteriorised and placed in a sterile saline moistened
gauze during illumination. The tumour size was measured
using vernier callipers. For illumination, two Perspex light
delivery blocks were used as light dispersers. One block
(3 x 2 x 1 cm) contained two cylindrical diffusing fibres (QLT
Phototherapeutics, Pearl River, NY, USA) and the other
block (3 x 1 x 1 cm) contained a single cylindrical diffusing
fibre (diffusing tip 2 cm long, 1.7 mm diameter). The three
fibres were coupled via a beam splitter to the dye laser
(Spectra Physics model 373) pumped by a 23 W Argon laser
(Spectra Physics model 171). Sulphorodamine B (Lambda
Physik) was used as the dye to obtain red laser light of 628 +
3 nm. The wavelength of the emitted light was calibrated
using a monochromator (Oriel model 77320). The output
from each fibre was adjusted to 100 mW cm-1 diffusing
length of the fibre (i.e. 200 mW per fibre), measured in an
integrating sphere with an optical power meter UDT 371.
For most experiments both blocks were placed in the lower
abdomen (total surface area (SA) 30 cm2). In some
experiments, however, only one block (containing two
diffusing fibres) was used for illumination of the tumour
area (illumination protocol lb). This gave an illumination SA
of 20 cm2, which was similar to the illumination area from
the minimally invasive illumination protocol 2 (see below). In
situ dosimetry measurements, using an isotropic light detector
coupled to an optical power meter, demonstrated a fluence
rate of 100 + 8 mW cm-2 on the surface of the blocks when
placed in the abdomen. During illumination, the tumour was
placed in contact with the Perspex blocks. After illumination,
the blocks were removed, the intestines were gently replaced
and the abdominal wall was closed in one layer with silk
sutures (3-0).
Illumination protocol 2 The rats were again anaesthetised
with an intramuscular injection of Aescoket plus and rectal
temperature was kept between 35 and 38°C using an electrical
heating pad. A small (<5 mm) median incision was made
just beneath the xiphoid process for the insertion of a balloon
catheter (100% silicone elastomer, with an outer diameter of
3.7 mm Ch 12 Ruisch, Kernen, Germany). A spherical
diffuser, emitting light at 200 mW, was fed through the
lumen of the catheter into the centre of the balloon. The
catheter was inserted in the lower abdomen and the balloon
inflated in situ with 5 ml of Intralipid solution (2.5%
Intralipid in saline), giving an SA of about 14 cm2. In situEfficacy of intraperitoneal PDT in a rat tumour model
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dosimetry revealed that the fluence rate on the surface of the
balloon was 90+40 mW cm-2. Illumination times were
adjusted to this mean fluence rate. After illumination the
balloon was deflated and the catheter removed. One to two
silk sutures (3-0) were used to close the abdominal wall.
During recovery rats were placed in tissue sacks to retain
body heat.
Treatment regimens
The efficacy of various IPPDT regimens, summarised in
Table I, was evaluated against the four control groups (no
treatment, photosensitiser alone, light alone (50 J cm-2) and
sham treatment). Initial experiments used illumination
protocol 1. Intravenous injection of Photofrin was compared
with i.p. administration and the influence of the hypoxic
toxin MMC, given 15 min before illumination was also
studied. The minimally invasive illumination protocol 2 was
subsequently compared with the invasive illumination
protocol lb (smaller surface area). As the balloon catheter
technique was less invasive, repeated treatments could be
performed and the tumour response after IPPDT with a
single illumination was compared with two or four
illuminations. For two fraction illumination schedules,
Photofrin (5 mg kg-') was injected 24 h before the first
illumination only or 24 h before each of two illuminations
separated by 1 week. A schedule of four illuminations with
two doses of Photofrin (2 x 5 mg kg-') separated by 1 week
was also tested. Illuminations were 24 and 48 h after each
Photofrin dose. The different PDT treatments were compared
with i.p. cisplatin treatment in maximum tolerable dose as
this represents the standard treatment for the CC531 tumour
in this tumour model. Toxicity prohibited the repetition of
cisplatin treatment at short time intervals.
Toxicity and tumour response
In previous toxicity studies (Veenhuizen et al., 1994), the
intestines were found to be the most sensitive intra-
abdominal organs and weight change appeared to be a
suitable toxicity parameter. Weight was therefore measured
and the condition of the rats was checked 2-3 times per
week throughout these experiments. Tumour measurements
were performed every 2 or 4 weeks. For these measurements
the rats were anaesthetised with ether and the tumours
measured in three orthogonal diameters with vernier callipers
during a small laparotomy. Once the tumour reached a mean
diameter of 15 mm the animals were sacrificed. The animals
were also sacrificed if there was more than 20% increase or
decrease in weight within 1 week. The animals were then
euthanised by an intracardial injection of ketamine under a
light ether anaesthesia. Tumour growth time was defined as
the time taken to increase by 5 mm in mean diameter (this
represents approximately an 8-fold increase in tumour
volume). Cure was defined as no visible tumour at 115
days. In the calculation of the regrowth times cures were not
included, so in those groups with a cure the mean regrowth
time is an underestimate of the total response.
Statistical methods
Means and standard errors of the mean were calculated for
tumour growth times for each group. Comparisons were
made by means of the Breslow statistics. This is a modified
version of the Kruskal -Wallis (or generalised Wilcoxon),
and allows the 'cures' to be incorporated in the analysis as
censored observations. The Kruskal-Wallis test was used to
compare the growth curves of the different repeated
treatments.
Results
Controls
For the control groups (no treatment, drug or light alone,
sham operation) there was a maximum weight loss of 2%
during the first 10 days. The tumour growth times for the
four control groups did not differ significantly and the mean
regrowth time for the four control groups was 20.4 (±1.4)
days (Table II). The possible influence of frequency of
Table I Different treatment regimens used in this study
Photosensitiser/drug/route Time between photosensitiser Light dosel
ofadministration and illumination/protocol no. no. of rats
Photofrin/i.v. 1 day/I 25Jcm-2/8
Photofrin/i.v. 1 day/i 50Jcm-2/8
Photofrin/i.p. 3h/i 25Jcm-2/8
Photofrin/i.p. 1 day/i 25Jcm-2/8
MMC alone/i.v. -/6
MMC/i.v. -/1 25 Jcm-2/5
Photofrin + MMC/i.v. 1 day/I 25Jcm-2/8
Photofrin/i.v. 1 day/lb 25Jcm-2/8
Photofrin/i.v. 1 day/2 25Jcm-2/8
Photofrin/i.v. 1 day/2 50Jcm-2/7
Photofrin/i.v. 1 day/2 75JCcm-2/8
Photofrin/i.v. 1,2 day/2 2 x 50Jcm 2/8
Photofrin/i.v. 1,2 day/2 2 x 75Jcm-2/7
2 x Photofrina/i.v. 1 day/2 2 x 5OJcm-2/8
2 x Photofrina/i.v. 1,2 day/2 4 x 5OJcm-2/7
cisplatin 2mgkg-'/i.p. - -/8
cisplatin 4mgkg-'/i.p. - -/8
aTwo doses ofPhotofrin (5mgkg 1) given 1 week apart.
Table II Regrowth times (time to increase 5mm in mean diameter from
day 0) for CC531 tumours in different control groups
Growth time
Treatment Mean+s.e.m. Cure/n
All control groups 20.4+1.4 0/31
No treatment 22.6+2.1 0/8
Photofrin alone 20.4+1.8 0/8
Light alone 22.6+3.7 0/7
Sham operation 16.3+2.7 0/8Efficacy of intraperitoneal PDT in a rat tumour model
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laparotomic tumour measurement on tumour growth was
assessed by comparing growth curves made from 2 weekly vs
4 weekly measurements. There were no differences between
these curves (data not shown). Therefore, all treatment
regimens can be compared with the mean regrowth times of
control tumours.
IPPDT using illumination protocol 1
Dose-finding studies with illumination protocol 1 (30 cm2
illuminated surface area), demonstrated that 75 J cm-2 given
24 h after Photofrin was just intolerable for tumour-bearing
rats. Fluences of 50 and 25 J cm-2 were well tolerated and
were therefore used in a first efficacy experiment. Both
treatments resulted in a 4% weight loss in the first week with
complete recovery within 2 weeks. These PDT schedules both
resulted in longer regrowth times than control groups,
significant for the 25 J cm-2 group; no light dose
dependency was found within this dose range (see Figure 1
and Table III).
Intraperitoneal administration of Photofrin was compared
with i.v. administration for illumination intervals of 3 h and 1
day. No significant difference in tumour response was noted
between the two injection routes for the 1 day interval (Table
II). For the 3 h interval after i.p. Photofrin administration
and regrowth time was significantly shorter than the regrowth
times for the 1 day interval with i.p. or i.v. administration of
bi)1
C,o
co
a)
E
0)
0
E
40
30
20
Controls 25 J cm 2
Figure 1 Regrowth times (means+ s.e.m.) of tumours treated
with IPPDT using the block (surface area 30cm2) illumination
technique (_) vs the minimally invasive catheter (surface area
14cm2) illumination technique (M). *One cure in this group
(not included in regrowth times). tLethal toxicity.
the photosensitiser (P-values 0.042 and 0.026 respectively).
The toxicity for the 3 h illumination interval was also
increased (weight loss of 6% in the first week).
IPPDT combined with MMC
MMC alone (1.5 mg kg-1) led to a significant increase in
tumour regrowth time (27.9 vs 20.4 days). When light (25
J cm-2) was added to MMC there was a small, not
significant, further increase in regrowth time to 32.8 days
(see Table III). Both these treatment schedules elicited the
same moderate toxicity of 3% weight loss in the first week.
When IPPDT was given within 15 min after the MMC
injection, the regrowth time increased to 37.7 + 6.8 days and
one cure was found. This was, however, not significantly
different from IPPDT alone. The toxicity also increased to
5% weight loss in the first week. Recovery from this weight
loss took 6 weeks in comparison with 2 weeks after PDT
alone. Eight weeks after treatment, 15% of the animals
treated with 1.5 mg kg-' MMC, singly or in combination,
had developed a chemical alveolitis leading to intolerable
morbidity.
Efficacy of minimally invasive illumination protocol 2
IPPDT using the single Perspex block illumination technique
with a surface area of 20 cm2 (protocol lb) was compared
with the minimally invasive technique using an inflatable
balloon catheter (protocol 2; SA 14 cm2). The mean tumour
regrowth time for a light dose of 25 J cm-2 using the invasive
illumination protocol lb was in the range of the controls and
less than the mean regrowth time after IPPDT with 25
J cm-2 delivered over the larger surface area with two
Perspex blocks (protocol 1). Using the balloon catheter with
the same total fluence (protocol 2), regrowth time increased
to 28.0+ 3.7 days (the same range as protocol 1, large
illumination surface area). The minimally invasive balloon
catheter technique (protocol 2) was less toxic than the
laparotomy block technique (protocol 1), so that higher
light doses could be administered. (IPPDT using illumination
protocol 2 with 75 J cm-2 gave only a 2% weight loss in the
first week, whereas this light dose was not tolerated using
protocol 1.) Increasing the light dose from 25 to 75 J cm-2
led to increased regrowth times with a significant difference
relative to controls for 75 J cm-2 (Figure 1).
Single vs repeated IPPDT
Tumour response to single or repeated treatments (balloon
catheter illumination protocol 2) was compared using 1 and
2x 75 J cm-2 and 1, 2 or 4 x 50 J cm-2. Photofrin was given
either as a single injection (5 mg kg-', i.v.) with illumination
at 1 and 2 days (two treatments) or as 2 x 5 mg kg- '
separated by 1 week, with illumination at 1 day after each
drug dose (two treatments) or at 1 and 2 days after each drug
dose (four treatments). Tumour growth curves after
treatment with 1, 2 and 4 x 50 J cm-2 are shown in Figure
2. Illumination with 2 x 50 J cm-2 with a 1 day interval gave
a better tumour response (longer regrowth times) than a
Table III Regrowth times (time to increase 5mm in mean diameter from day 0) for CC531 tumours treated
with IPPDT+MMC using two Perspex blocks to illuminate the lower abdomen (illuminated SA = 30cm2)
Growth time P-value in comparison
Treatment Mean+s.e.m. Cure/n with controls
Controls 20.4+1.4 0/31
i.v. Photofrin + 25Jcm-2, 1 day 31.0+3.2 0/8 0.010
i.v. Photofrin + 50Jcm 2, 1 day 30.9+5.6 1/8 0.238
i.p. Photofrin + 25Jcm-2, 3 h 26.4+4.6 0/8 0.909
i.p. Photofrin + 25Jcm-2, 1 day 30.1+2.5 0/8 0.040
MMC alone 27.9+2.0 0/6 0.043
MMC + 25Jcm 2 1 day 32.8+1.9 0/5 0.011
Photofrin + MMC + 25Jcm-2, 1 day 37.7+6.8 1/8 0.004
I -
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lumination, although this was not significant maximal tolerable range (25-50 J cm-2 to the lower
) (Table IV). Two times 50 J cm-2 with a 1 week abdomen, 30 cm2) a significant tumour effect, but no light
and two Photofrin injections resulted in regrowth dose dependency, was found with the invasive illumination
nilar to 1 x 50 J cm-2. The tumour regrowth times protocol 1. The minimally invasive illumination protocol 2
50 J cm-2 and 2 x Photofrin were longer than for (14 cm2) enabled us to increase the light dose further, and a
cm-2 (not significant, P=0.076) and longer than significant growth delay was achieved with 75 J cm-2.
achieved with a maximum tolerable dose ofcisplatin Efficacy of IPPDT with acceptable toxicity has therefore
)le IV). Using the Kruskal-Wallis test for the been demonstrated in this model.
,on of the slopes of the different growth curves One rather surprising finding was the marked influence of
2) there was, however, a statistically significant the illuminated area using the invasive illumination protocol
between repeated and single treatment (P-value 1. For a given light dose per unit area, an illumination field
The largest difference was found for the 4x 50 of 30 cm2 gave greater tumour response than the smaller,
ompared with the single treatment (P-value 0.0012). 20 cm2 field (growth delays of 28.0+3.7 days vs 21.2+ 1.5
repeated treatments were well tolerated, with a days). This was not predicted as both illumination fields
n weight loss of 5%. should adequately cover a tumour of 5 mm diameter. It is
possible that the larger illumination field produced a greater
vascular destruction in the stroma surrounding the tumour
an and that this contributed to the tumoricidal effect.
Interestingly, the balloon catheter illumination protocol 2,
Ll superficial character of PDT damage makes it with a SA of only 14 cm2, was as effective as the invasive
l applicable for small localised tumours such as those illumination protocol 1 (SA 30 cm2), for a given light dose
peritoneum. Normal tissue toxicity is restricted per unit area. Presumably other factors, such as increased
of the limited penetration depth of the light used light scatter in the closed illumination system, played a major
the currently used photosensitisers. However, with role here. These results emphasise the difficulties in
large surface area of thin-walled organs, such as the comparing tumour efficacy after a given PDT 'dose' for
, is treated and these epithelia appear to be different illumination techniques.
le to PDT (Veenhuizen et al., 1994; DeLaney et Intraperitoneal administration of the photosensitiser was
'. Intestinal toxicity, measured by weight loss, limited tested with the idea that direct contact ofphotosensitiser and
fluences that could be used in our study; within this i.p. tumour may improve drug uptake and hence tumour
response. No difference in response to IPPDT was found in
our tumour model using the i.p. vs i.v. route of
administration of sensitiser. However, in this model the
tumour is embeaaea in iat, wnicn may impair airect
photosensitiser uptake in tumour cells. The only published
study on i.p. vs i.v. administration of photosensitiser
described drug distribution results for abdominal normal
tissues and a murine i.p. tumour (Perry et al., 1991). These
authors found no difference in intestinal uptake of Photofrin
at 3 or 24 h for the different routes of administration, but
there was an increased sensitiser elimination half time in the
tumour for the i.p. route.
In our study, MMC in combination with PDT resulted in
longer tumour regrowth times than were achieved with MMC
^,anr TDPnT'r ela M Ta al1z1tirne fAttY-r^xxYf1h AAlaxA -aione or irrij i aione. tne auuitionai enIect growLn aeIay), I I I I I I however, could be explained by simple additive toxicities
0 0 10 20 30 40 50 60 70 without synergism. This contrasts with the results of Baas et
Time after treatment (days) al. (1994) and van Geel et al. (1995), who found a substantial
increase in tumour response for combined PDT and MMC of Growth curves of CC 531 tumours treated with IPPDT sbuaeu os uor.I hs tde h D ih
e minimal access balloon catheter illumination technique. subcutaneous mouse tumours. In these studies the PDT light
trols; *, 1 x 50 Jcm-2; V, 2 x 50 jCM-2 1 day interval dose required for 50% cure could be reduced by a factor of 2
the illuminations; A, 4 x 50 Jcm-2 2 Photofrin injections when MMC was given 15 min before illumination. The
Fore first and third illumination separated by 1 week. enhanced tumour response from the combined treatment was
*epresent mean values + 1 s.e.m. (n=7 or 8). much larger than could be explained by additive toxicities
Table IV Regrowth times (time to increase 5mm in mean diameter from day 0) for CC531 tumours
treated with IPPDT using a single Perspex block (SA = 20cm2, protocol Ib) or inflatable balloon
catheter (SA= 14cm2, protocol 2) to illuminate the lower abdomen
Growth time P-value in comparison
Treatment/illumination protocol Mean+s.e.m. Cure/n with controls
Controls 20.4+1.4 0/31
Phota + 25Jcm-2/lb 21.2+1.5 0/8 0.775
Phota + 25Jcm-2/2 28.0+3.7 0/8 0.157
Phota + 5OJcm 2/2 26.8+2.2 0/7 0.137
Phota + 75Jcm-2/2 36.7+4.3 0/8 <0.0005
Phota + 2 x 5OJcm-2/2 32.2+3.0 1/8 0.02
Phota + 2 x75Jcm-2/2 30.7+2.9 1/7 0.005
Photb + 4 x 5OJcm-2/2 47.2+8.1 0/7 0.0405
Photc + 2 x 5OJcm-22 24.8+2.5 1/8 0.352
cis-Platinum 2mgkg-, i.p. 42.8+3.6 0/8 <0.0005
cis-Platinum 4mgkg , i.p. 40.6+4.5 1/8 <0.0005
aPhotofrin, 5mgkg-',i.v. at 24h before (first) illumination. bPhotofrin, 5mgkg 1, i.v. at 24h before
first and third illumination (separated by one week). cPhotofrin, 5mgkg ',i.v. at 24h before first and
second illumination (separated by one week).
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and the authors proposed an interaction between the two
modalities, possibly based on PDT-induced h-poxia activat-
ing the MMC. Van Geel et al. (1994) had measured a
substantial decrease in the vascular perfusion shortly after
PDT of their RIFI tumour. In our tumour model we do not
know whether hypoxia is induced after PDT. In the near
future we will also investigate the oxygenation of this tumour
model.
PDT of a large surface area will always be limited by its
toxicit.- For the cure of multiple tumours disseminated on
the peritoneum a single PDT treatment. limited by the
toxicity, will probably not be enough (Tochner et al. 1985:
1986). To enable repeated PDT treatments to be given, the
minimally invasive illumination protocol 2 w-as developed.
The advantage of this technique is that it offers the possibility
of repetition of the procedure with relatively short time
intervals. Our results for the repeated IPPDT treatments
demonstrated that a given light dose (50 J cm-') repeated at
a short time interval (I day) led to a significant increase in
grow-th delay w-ith respect to a single treatment. A larger
interval of 1 w-eek appeared to be too long. possibly because
in this w-eek the tumour has grown substantially (volume
doubling time of this tumour is about 1 w-eek). The schedule
of four illuminations (total light dose 200 J cm-) with two
photosensitiser doses over a total time of 1 week was.
however ver- effective and well tolerated.
To optimise IPPDT. the tumour to normal tissue
photosensitiser ratio should be increased. To achieve this
goal. the use of an immunoconjugate of the photosensitiser
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with a tumour specific antibody is an attractive possibility.
Photofrin does have an absorption peak at 514 nm and the
use of this green (less penetrating light) might decrease
toxicity and permit higher light doses to be given. but this
w-ill only be suitable for very small tumours. Combinations of
red and green light could offer the best chance for effective
tumoncidal light doses to be delivered wAith acceptable
toxicitv. In addition fractionation of illumination w-ith short
time intervals may allow- normal tissues to recover before the
tumour has regrown. All these strategies for optimisation
need to be fully investigated in preclinical models before new
clinical protocols are initiated.
In conclusion. IPPDT can be effective in delaying tumour
growth but normal tissue toxicity seems to preclude cure. in
this tumour model. from a single application of IPPDT.
Repeated treatments can lead to increased growth delay and
MMC can be used to enhance the tumour effect.
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